TGTX

Business Context and Reporting Period

Company: Manhattan Pharmaceuticals, Inc. (Note: Request metadata listed "TG THERAPEUTICS, INC." but the filing text identifies the registrant as Manhattan Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Stage: Development Stage Company. The Company has generated no revenue to date and focuses on biopharmaceutical research and development.
Key Event: On March 8, 2010, the Company completed a merger with Ariston Pharmaceuticals, Inc., acquiring its product candidates (AST-726 and AST-915) and assuming related liabilities.

Key Financial Metrics

Debt Obligations: Significant debt includes $15.45 million in Convertible 5% notes (assumed from Ariston), $1.66 million in Secured 12% notes (current portion), and $1.0 million in ICON convertible notes.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by 114% to $1.63 million from $0.76 million in Q1 2009. This was primarily driven by a $0.94 million non-cash charge related to the change in fair value of derivative liabilities.
• Liquidity Improvement: Cash and cash equivalents increased from $18,000 at December 31, 2009, to $2.02 million at March 31, 2010. This was due to a $2.1 million equity financing and $0.52 million cash acquired in the Ariston merger.
• Balance Sheet Expansion: Total assets increased from $0.37 million to $20.08 million, largely due to the acquisition of $17.74 million in In-Process Research and Development (IPR&D) from Ariston.
• Liabilities: Total liabilities surged from $7.15 million to $27.60 million, reflecting the assumption of Ariston's debt and the recording of derivative liabilities associated with new financing.

Outlook, Risks, and Management Commentary

• Going Concern: Management states that substantial doubt exists regarding the Company's ability to continue as a going concern. They believe current resources are sufficient only through the end of 2010. Additional equity or debt financing is required to sustain operations into 2011.
• Financing Activity: In March 2010, the Company raised approximately $2.55 million in gross proceeds via a private placement of units (common stock and warrants). A final closing occurred in April 2010.
• Joint Venture Dispute: A significant dispute exists with Nordic Biotech Venture Fund II (Nordic), the partner in the Hedrin Joint Venture. Nordic filed an amended Schedule 13D claiming beneficial ownership of 65.5% of the Company's stock based on anti-dilution calculations, whereas the Company calculates ownership at 42.9%. This dispute relates to the valuation of the 2010 equity financing.
• Product Pipeline:
  • Hedrin: Development for head lice treatment is ongoing via the Hedrin JV. The FDA classified it as a Class III medical device, requiring a Premarket Approval (PMA) and clinical trials.
  • Ariston Assets: The merger added AST-726 and AST-915 to the portfolio. Milestone shares are contingent on FDA filings and approvals.
  • Topical GEL: The Company is exploring the development of a proprietary topical gel for psoriasis following the termination of the PTH (1-34) program.

Investor Verification Checklist

• Going Concern Status: Verify the Company's ability to secure additional financing before the end of 2010 to avoid insolvency.
• Nordic Dispute: Monitor the resolution of the anti-dilution calculation dispute with Nordic, which could significantly alter the capitalization table and voting control.
• Derivative Liabilities: Assess the impact of the $4.62 million derivative liability on future earnings, as changes in stock price will result in non-cash charges or gains.
• Debt Covenants: Review the terms of the Secured 12% notes and Convertible 5% notes, particularly regarding interest payments and conversion features.
• Regulatory Progress: Track the status of the Hedrin PMA application and the FDA's response to non-clinical questions raised in April 2010.